| Therapeutic use of the high-density lipoprotein protein and peptides. | |
| | |
MedLine Citation:
|
PMID: 16503760 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the novel techniques of coronary evaluation. A number of reports have examined the potential therapeutic properties of the synthetic HDLs prepared by complexing recombinant apolipoprotein (apo) A-I(Milano), a variant form of native apoA-I, with phospholipids. The availability of synthetic HDL complexes containing recombinant apoA-I(Milano) has opened up a new era of therapeutic management for coronary disease. HDL formulations of recombinant apoA-I(Milano)-phospholipid complexes have clearly shown rapid regression of a focal carotid atheroma as well as powerful protection from myocardial infarction in a rabbit model. In a pilot study, ETC-216 showed a significant reduction in coronary plaque burden after five weekly treatments, assessed by intravascular ultrasound in patients with acute coronary syndrome. Other therapeutic options of HDL therapy have recently became available. |
| | |
Authors:
|
Marta Marchesi; Cesare R Sirtori |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 15 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-02-28 Completed Date: 2006-04-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 227-41 Citation Subset: IM |
Affiliation:
|
Department of Pharmacological Sciences, University of Milan, 20133 Milan, Italy. Marta.Marchesi@unimi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Apolipoprotein A-I / therapeutic use Arteriosclerosis / drug therapy, pathology Coronary Disease / drug therapy, pathology Humans Lipoproteins, HDL / therapeutic use* Peptides / therapeutic use* Phosphatidylcholines / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein A-I; 0/ETC216; 0/Lipoproteins, HDL; 0/Peptides; 0/Phosphatidylcholines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Recent developments in antibacterial drug discovery: microbe-derived natural products--from collecti...
Next Document: Recent findings concerning thiazolidinediones in the treatment of diabetes.